{
  "response": {
    "text": "Based on the search results, the clinical trial NCT02294461 (also known as Asian PREVAIL) primarily investigated the efficacy of Enzalutamide (brand name XTANDI) compared to a placebo in patients with metastatic castration-resistant prostate cancer (mCRPC).\n\nThe active ingredient in the XTANDI regimen is Enzalutamide.\n\nTherefore, the ingredient starting with the letter \"E\" that is part of the more effective regimen is Enzalutamide.\n\nINGREDIENT: ENZALUTAMIDE",
    "citations": []
  }
}